John B Porter

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint A risk-benefit assessment of iron-chelation therapy
    J B Porter
    Department of Haematology, University College London, England
    Drug Saf 17:407-21. 1997
  2. ncbi request reprint Concepts and goals in the management of transfusional iron overload
    John B Porter
    Department of Haematology, University College London, London, UK
    Am J Hematol 82:1136-9. 2007
  3. doi request reprint Challenges of adherence and persistence with iron chelation therapy
    John B Porter
    Department of Haematology, University College London, UCL Cancer Institute, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Int J Hematol 94:453-60. 2011
  4. pmc Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
    J B Porter
    UCL Cancer Institute, Department of Haematology, University College London, 72 Huntley Street, London, UK
    Ann Hematol 92:211-9. 2013
  5. pmc Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
    Yesim Aydinok
    Department of Pediatric Hematology, Ege University Faculty of Medicine, 35100 Bornova, Izmir, Turkey
    Haematologica 97:835-41. 2012
  6. ncbi request reprint Monitoring and treatment of iron overload: state of the art and new approaches
    J B Porter
    University College London, Department of Haematology, London, UK
    Semin Hematol 42:S14-8. 2005
  7. pmc Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
    John B Porter
    University College London, London, UK
    Eur J Haematol 87:338-48. 2011
  8. ncbi request reprint Deferasirox--current knowledge and future challenges
    John B Porter
    Department of Haematology, University College London, London, United Kingdom
    Ann N Y Acad Sci 1202:87-93. 2010
  9. ncbi request reprint Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies
    John B Porter
    Red Cell Disorders Unit, University College London Hospital, 250 Euston Road, London, UK
    Hematol Oncol Clin North Am 24:1109-30. 2010
  10. ncbi request reprint Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use
    J B Porter
    Department of Haematology, University College London, London, United Kingdom
    Ann N Y Acad Sci 1054:155-68. 2005

Detail Information

Publications46

  1. ncbi request reprint A risk-benefit assessment of iron-chelation therapy
    J B Porter
    Department of Haematology, University College London, England
    Drug Saf 17:407-21. 1997
    ..There remains an urgent need to identify an orally active chelator regimen that is as effective as deferoxamine and has an acceptable degree of tolerability...
  2. ncbi request reprint Concepts and goals in the management of transfusional iron overload
    John B Porter
    Department of Haematology, University College London, London, UK
    Am J Hematol 82:1136-9. 2007
    ....
  3. doi request reprint Challenges of adherence and persistence with iron chelation therapy
    John B Porter
    Department of Haematology, University College London, UCL Cancer Institute, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Int J Hematol 94:453-60. 2011
    ....
  4. pmc Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
    J B Porter
    UCL Cancer Institute, Department of Haematology, University College London, 72 Huntley Street, London, UK
    Ann Hematol 92:211-9. 2013
    ..The higher incidence of gastrointestinal AEs at lower iron burdens requires further investigation...
  5. pmc Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response
    Yesim Aydinok
    Department of Pediatric Hematology, Ege University Faculty of Medicine, 35100 Bornova, Izmir, Turkey
    Haematologica 97:835-41. 2012
    ..We undertook carefully timed measurements of non-transferrin bound iron to explore the origin of chelatable iron and to predict clinical response to deferiprone...
  6. ncbi request reprint Monitoring and treatment of iron overload: state of the art and new approaches
    J B Porter
    University College London, Department of Haematology, London, UK
    Semin Hematol 42:S14-8. 2005
  7. pmc Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
    John B Porter
    University College London, London, UK
    Eur J Haematol 87:338-48. 2011
    ..However, data are limited for rare transfusion-dependent anaemias, and it remains to be elucidated if response differs, depending on whether the anaemia has a primary haemolytic or production mechanism...
  8. ncbi request reprint Deferasirox--current knowledge and future challenges
    John B Porter
    Department of Haematology, University College London, London, United Kingdom
    Ann N Y Acad Sci 1202:87-93. 2010
    ....
  9. ncbi request reprint Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies
    John B Porter
    Red Cell Disorders Unit, University College London Hospital, 250 Euston Road, London, UK
    Hematol Oncol Clin North Am 24:1109-30. 2010
    ..This article scrutinizes evidence for response rates to deferoxamine, deferiprone (and combinations), and deferasirox...
  10. ncbi request reprint Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use
    J B Porter
    Department of Haematology, University College London, London, United Kingdom
    Ann N Y Acad Sci 1054:155-68. 2005
    ..Here the benefits of continuous DFO on heart function occur before changes in T2*-visible storage iron, consistent with early removal of a toxic labile iron pool within myocytes...
  11. ncbi request reprint Deferasirox: An effective once-daily orally active iron chelator
    John B Porter
    Thalassaemia and Sickle Unit, University College London Hospitals, United Kingdom
    Drugs Today (Barc) 42:623-37. 2006
    ..Deferasirox is currently registered as monotherapy for transfusional iron overload in more than 65 countries worldwide, including the United States and in the European Union...
  12. pmc Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
    John Porter
    University College London, London, UK
    Eur J Haematol 80:168-76. 2008
    ..Dosage was determined by baseline liver iron concentration (LIC)...
  13. doi request reprint Deferasirox: an update
    John B Porter
    Department of Haematology, University College London, London, UK
    Hemoglobin 33:S70-5. 2009
    ..Cardiac substudies of this trial, in >100 patients with established mild to moderate myocardial iron loading by T2*, show a significant reduction in cardiac iron...
  14. ncbi request reprint Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia
    John B Porter
    Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK
    Best Pract Res Clin Haematol 15:329-68. 2002
    ..The value of monitoring to decrease morbidity from iron overload is also discussed, particularly with reference to the estimation of iron deposition in the pituitary...
  15. doi request reprint Optimizing iron chelation strategies in beta-thalassaemia major
    John B Porter
    Department of Haematology, University College London, London, UK
    Blood Rev 23:S3-7. 2009
    ..Further, prospective data show that myocardial iron can be effectively decreased with this chelation treatment...
  16. pmc Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
    Dudley J Pennell
    Royal Brompton Hospital, London, UK
    Haematologica 97:842-8. 2012
    ..Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important...
  17. pmc A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)
    Dudley J Pennell
    Royal Brompton Hospital, London, United Kingdom
    Blood 123:1447-54. 2014
    ..4%) and deferoxamine (30.8%). CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial iron removal. This trial is registered at www.clinicaltrials.gov as #NCT00600938. ..
  18. ncbi request reprint Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron
    Mark A Westwood
    Cardiovascular MR Unit, Royal Brompton Hospital and Imperial College, London, United Kingdom
    J Magn Reson Imaging 25:1147-51. 2007
    ..To determine the reference range in thalassemia major (TM) for left ventricular (LV) function...
  19. pmc Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
    Dudley J Pennell
    Royal Brompton Hospital, London, UK
    Haematologica 96:48-54. 2011
    ..Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial...
  20. pmc Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
    Patricia Evans
    Department of Hematology, University College London Medical School, London, United Kingdom
    Transl Res 156:55-67. 2010
    ..We conclude that at clinically relevant concentrations, DFP enhances plasma NTBI chelation with DFO by rapidly accessing and shuttling NTBI fractions that are otherwise only slowly available to DFO...
  21. pmc Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload
    John Paul Carpenter
    Cardiovascular MR Unit, Royal Brompton Hospital, London, London, UK
    J Cardiovasc Magn Reson 12:24. 2010
    ..We aimed to define reference ranges for right ventricular (RV) volumes, ejection fraction (EF) in thalassemia major patients (TM) without myocardial iron overload...
  22. ncbi request reprint Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy
    Mark A Westwood
    Cardiovascular MR Unit, Royal Brompton Hospital and Imperial College, London, UK
    J Magn Reson Imaging 26:564-8. 2007
    ....
  23. pmc On T2* magnetic resonance and cardiac iron
    John Paul Carpenter
    Royal Brompton and Harefield NHS Trust, London, SW3 6NP, UK
    Circulation 123:1519-28. 2011
    ....
  24. ncbi request reprint Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
    Lisa J Anderson
    Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK
    Br J Haematol 127:348-55. 2004
    ..Myocardial T2* improves in concert with LV volumes and function during recovery, but iron clearance from the heart is considerably slower than from the liver...
  25. pmc On myocardial siderosis and left ventricular dysfunction in hemochromatosis
    John Paul Carpenter
    Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London, SW3 6NP, UK
    J Cardiovasc Magn Reson 15:24. 2013
    ..Most previous data on myocardial siderosis in HC has come from post-mortem studies...
  26. doi request reprint Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease
    John B Porter
    Department of Haematology, University College London, London, UK j porter ucl ac uk
    Hemoglobin 33:S37-45. 2009
    ..Further understanding of these mechanisms may help in designing strategies to decrease extrahepatic iron distribution in TM...
  27. ncbi request reprint Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
    Bernard A Davis
    Department of Haematology, Royal Free and University College Medical School, and Department of Research and Development, University College London Hospitals, United Kingdom
    Blood 104:263-9. 2004
    ..Sequential quantitative monitoring of LVEF is valuable for assessing cardiac risk and for identifying patients with thalassemia major who require intensified chelation therapy...
  28. ncbi request reprint Results of long term iron chelation treatment with deferoxamine
    Bernard A Davis
    Department of Haematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK
    Adv Exp Med Biol 509:91-125. 2002
  29. ncbi request reprint Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes
    Y Mundee
    Department of Haematology, University College London Medical School, London, UK
    Clin Lab Haematol 23:149-54. 2001
    ..The method is a simple, rapid, convenient, reproducible and useful way of determining F cell, reticulocyte and F reticulocyte levels in sickle cell and thalassaemic patients...
  30. pmc Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan
    Maciej W Garbowski
    Haematology Department, University College London Hospitals, London, UK
    J Cardiovasc Magn Reson 16:40. 2014
    ..These important advances allow more accurate calculation of liver T2* especially in patients with high LIC...
  31. ncbi request reprint Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase
    R Kayyali
    Department of Clinical Haematology, University College London Medical School, London WC1E 6HX, United Kingdom
    J Biol Chem 276:48814-22. 2001
    ..It is anticipated that such compounds will possess a superior therapeutic safety margin to currently available bidentate HPOs...
  32. ncbi request reprint Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy
    J B Porter
    Department of Clinical Haematology, University College, London, UK
    Blood 88:705-13. 1996
    ..This was followed by a slower return to pretreatment levels, usually between 6 and 12 hours, which was faster in TI than in TM. This marked NTBPI lability supports the use of continuous rather than intermittent DFO in high risk patients...
  33. ncbi request reprint Simplified flow cytometric method for fetal hemoglobin containing red blood cells
    Y Mundee
    Department of Haematology, University College London Medical School, London, UK
    Cytometry 42:389-93. 2000
    ..It can also be applied as a fetal cell assay in fetomaternal hemorrhage...
  34. ncbi request reprint Deferoxamine pharmacokinetics
    J B Porter
    Department of Haematology, University College of London, England
    Semin Hematol 38:63-8. 2001
    ..Because iron overload is likely to become an increasing issue in patients with sickle cell disorders, studies of the pharmacokinetics and metabolism of deferoxamine in this patient group are needed...
  35. doi request reprint Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome
    Ratna Chatterjee
    Institute for Women s Health, University College London, London, UK
    Br J Haematol 159:462-71. 2012
    ..In conclusion, histomorphometry data suggest that TM patients have a distinct pathology of high turnover bone disease compared to TI patients, who have low-turnover disease...
  36. ncbi request reprint Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera
    Robert W Evans
    Metalloprotein Research Group, Nutritional Sciences Division, King s College London, New Hunt s House, London, SE1 1UL, UK
    J Biol Inorg Chem 13:57-74. 2008
    ....
  37. ncbi request reprint Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs
    S Desigan
    Department of Imaging, University College London Hospitals, NHS Foundation Trust, 235 Euston Road, London NW1 2BU, UK
    Skeletal Radiol 35:95-102. 2006
    ..The aim of this study was to test our observation that back pain in thalassemic patients could be caused by premature and extensive lumbar degenerative disc disease, when compared to non-thalassemic patients with back pain...
  38. ncbi request reprint Role of FcgammaRI (CD64) in erythrocyte elimination and its up-regulation in thalassaemia
    E Wiener
    Department of Haematology, Imperial College School of Medicine, St Mary s Campus, London
    Br J Haematol 106:923-30. 1999
    ..The results suggest that, in thalassaemia, up-regulated FcgammaRI on mononuclear phagocytes plays a role in their interaction with erythrocytes and that this process can be modified by cytokines...
  39. ncbi request reprint A retrospective observational study of pre-operative sickle cell screening
    P L Pemberton
    University College London Hospitals, Mortimer Street, London W1T AA, UK
    Anaesthesia 57:334-7. 2002
    ..We propose a universal screening policy be implemented in high-risk areas...
  40. ncbi request reprint Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators
    Zu D Liu
    Department of Pharmacy, King s College London, Franklin Wilkins Building, 150 Stamford Street, London SE1 9NN, UK
    J Med Chem 45:631-9. 2002
    ....
  41. ncbi request reprint Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major
    Mark A Westwood
    Cardiovascular MR Unit, Royal Brompton Hospital and Imperial College, Sydney Street, London SW3 6NP, UK
    J Magn Reson Imaging 22:229-33. 2005
    ..To compare left ventricular (LV) diastolic function with myocardial iron levels in beta thalassemia major (TM) patients, using cardiovascular magnetic resonance (CMR)...
  42. ncbi request reprint Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major
    Alan R Cohen
    Children s Hospital of Philadelphia, PA 19104 4399, USA
    Blood 111:583-7. 2008
    ..This study is registered at http://clinicaltrials.gov as NCT00061750...
  43. ncbi request reprint Deferiprone and hepatic fibrosis
    Gary M Brittenham
    Blood 101:5089-90; author reply 5090-1. 2003
  44. ncbi request reprint Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform
    Esther M G Jacobs
    Department of Clinical Chemistry, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands
    Anal Biochem 341:241-50. 2005
    ....